Top news of the week: 04.02.2021.
Companies And Industries
Sangamo nabs new R&D lead from Lilly's 'special force' research unit
More than half a year after its former R&D chief unexpectedly hit the exit, Sangamo has tapped ex-Eli Lilly exec Rob Schott, M.D., as senior vice president and head of development.
How COVID-19 Has Permanently Changed The World of Medical Research
A spirit of urgency and collaboration broke down traditional informational barriers as industry and academia organized like never before in modern history to develop a vaccine in just nine ...
Horizon inks $3B deal to buy AstraZeneca spinout Viela for autoimmune drugs
Horizon Therapeutics has struck a $3 billion deal to buy AstraZeneca spinout Viela Bio. The takeover will give Horizon a clutch of clinical-phase autoimmune and inflammatory disease drug ...
Clinical Catch-Up: January 25-29
It was a busy week for clinical trial news. Read on for more information.
Win a BIO Digital Registration + Exposure to a Global Biotech Audience - BIO Digital | BIO
Enter the Buzz of BIO Contest to make connections that take your product to the next phase.
Neurocrine exits $165M Parkinson's pact with Voyager after FDA hold
In one of the top biopharma licensing deals of 2019, Neurocrine Biosciences bet $165 million—and promised $1.7 billion more—on a gene therapy partnership with Voyager Therapeutics. ...
Myths of Vaccine Manufacturing
In the last few days, the question of why more drug companies haven't been enlisted for vaccine production has come up. It's mostly due to this tweet: The problem is, as far as I can ...
Blurring Lines: Between Vaccine Urgency in a Pandemic and Research and Regulation Ethics
How fast is too fast for vaccine approval?